Concepedia

Dose Modification Assessment

Dose Modification Assessment is a systematic clinical evaluation method used in chemotherapy preparation to determine necessary adjustments to drug dosage based on individual patient factors, disease characteristics, and treatment response, distinguishing it from general dosing protocols by its focus on personalized modification criteria.

113

Publications

4.9K

Citations

882

Authors

420

Institutions

Publications per year

2017–2026

34

Parents

Publications

113

Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices

Gary H. Lyman, David C. Dale, Jeffrey Crawford · Journal of Clinical Oncology · 2003 · 463 citations

, , +16

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · British Journal of Haematology · 2009 · 308 citations

, , +14

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

Stacey Stein, Edward James, Yanhong Deng et al. · British Journal of Cancer · 2016 · 215 citations · Full text

, , +17

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

Barbara Weber, Charles Vogel, Stephen E. Jones et al. · Journal of Clinical Oncology · 1995 · 193 citations

, , +14

Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

Roger R. Reddel, Richard Kefford, Justin Grant et al. · PubMed · 1982 · 188 citations

, , +16

1–5 of 113

Authors

882

  1. LN
    Lisa Noll

    Harvard University, United States

    2 publications · 34 citations

    2

    h-index

  2. LB
    Lori Buswell

    Harvard University, United States

    2 publications · 34 citations

    2

    h-index

  3. JF
    Jesús F. San Miguel

    Universidad de Salamanca, Spain

    2 publications · 325 citations

    2

    h-index

  4. JK
    Jeremy Kortmansky

    Memorial Sloan Kettering Cancer Center, United States

    2 publications · 232 citations

    2

    h-index

  5. RR
    Ronald R. Salem

    Yale University, United States

    2 publications · 232 citations

    2

    h-index

1–5 of 882

Institutions

420

  1. Harvard University

    Cambridge, United States

    4 h-index

    10 publications

    188 citations

  2. Memorial Sloan Kettering Cancer Center

    New York, United States

    4 h-index

    18 publications

    652 citations

  3. Pfizer (United States)

    New York, United States

    3 h-index

    7 publications

    123 citations

  4. Institut Català d'Oncologia

    Barcelona, Spain

    3 h-index

    2 publications

    113 citations

  5. University of Ulsan

    Ulsan, South Korea

    3 h-index

    4 publications

    59 citations

  6. Ulsan College

    Ulsan, South Korea

    3 h-index

    4 publications

    59 citations

  7. University Hospital of Bern

    Bern, Switzerland

    3 h-index

    2 publications

    58 citations

  8. University of Michigan

    Ann Arbor, United States

    3 h-index

    8 publications

    292 citations

1–8 of 420

Venues

  1. Journal of Clinical Oncology

    12 publications · 1K citations

    10

    h-index

  2. PubMed

    Repository · 9 publications · 465 citations

    9

    h-index

  3. Cancer

    5 publications · 181 citations

    5

    h-index

  4. British Journal of Cancer

    BJC · 4 publications · 369 citations

    4

    h-index

  5. Oncology

    3 publications · 67 citations

    3

    h-index

1–5